To mark 40 years since the approval of the first monoclonal antibody for therapeutic use, this conference will highlight the major advances that have accompanied the field. While innovation continues with traditional formats, these large molecules now encompass conjugates, multiple targets, target selectivity and de novo design alongside combinations and innovative dosing paradigms. This conference will highlight the innovations that have afforded antibodies unparalleled success in combatting rare disease for a few patients to deployment to millions in record time during the recent pandemic. By sharing the major strides gained across different modalities, this conference aims to bring together the innovators who can apply these advances to new clinical indications for patients.

Attendees will be exposed to the most cutting-edge technologies employed in antibody development. Each session will build and expand on the last allowing for deep interrogation of the innovations across indications and platforms. First, the conference will delve into multispecific antibodies and the use of combinations or engagement of specific targets for specific indications. Next, selectively active antibodies and novel platforms for conditional engagement will be discussed. A deep discussion on exogenous targets and advancements in pathogens will be included. Finally, a discussion on novel scaffolds will include discussion on other formats and antibody-like molecules. Further, this meeting is being held concurrently with the “Computational Drug Discovery” conference and includes a joint session for attendees to hear from pioneers in the field to explore how computational approaches to antibody design can be applied across these modalities.